Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2 1

Status

Recruiting 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 69INDUSTRY 6NIH 5NETWORK 2

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Dermatologic 1Breast 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Breast Neoplasms 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × fludarabine phosphate × 90 days × Clear all
NCT05712278 2026-06-05

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Sanofi

Phase 1 Terminated
7 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07627698 2026-06-04

DUET-MEL

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT06500273 2026-06-02

ALPHA3

Allogene Therapeutics

Phase 2 Recruiting
250 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07486089 2026-03-20

DUAL-NK-BC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Fate Therapeutics

Phase 1 Active not recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT06153251 2026-03-18

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1 Recruiting
187 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡